Figure 3.

Population‐level association between mean HbA1c level and hypoglycaemia rate in patients with (A) type 1 diabetes and (B) type 2 diabetes based on data from the maintenance period of the SWITCH trials.

Glargine U100, insulin glargine 100 units/mL; PYE, patient‐year of exposure.

Symptomatic hypoglycaemia^a in the maintenance period was analyzed using a Poisson model with patient as random effect; treatment, period, sequence and time of dosing as fixed effects; mean HbA1c in the maintenance period and mean HbA1c in the maintenance period squared as covariates; and exposure time to trial drug in each hypoglycaemia counting period as an offset term. The population‐level associations between mean HbA1c level and symptomatic hypoglycaemia rate were estimated from these models. Data shown are the estimated population mean and the 95% confidence interval.

^aSymptomatic hypoglycaemia was defined as severe (requiring third‐party assistance)23 as confirmed by an event adjudication committee or blood glucose‐confirmed (<3.1 mmol/L [56 mg/dL]) accompanied by symptoms